USP5 and neoplasm: We therefore assessed the anti-tumor efficacy of the USP5 inhibitor, EOAI3402143, an inhibitor has shown to possess the anti-tumor activity in several preclinical models, including colorectal cancer, melanoma, and B-cell malignancies.39,45,46 We first established mouse subcutaneous xenograft models using NICD1-overexpressed human ESCC cells and treated the mice with EOAI3402143, as shown in Fig. 6a.